Susan L. Hogue
PharmD, MPH
VP, STRATEGIC PARTNERSHIPS
Chapel Hill, NC
I alone cannot change the world, but I can cast a stone across the water to create many ripples."- Mother Teresa
Areas of Expertise
- Market Access
- Biopharmaceuticals
- Payer/HTA decision maker considerations
- Innovative communication solutions for payer decision makers
- Outcomes Research and Evidence Generation
Biography
is Vice President of Strategic Partnerships at AESARA, Inc. who has over 20 years of pharmaceutical industry experience.
Susan has 7 years of market access consulting experience coupled with 18 years in the pharmaceutical industry where she conducted extensive research in Global Health Outcomes and Market Access and has worked at all levels of product development across a wide array of therapy areas. During her career, she has been responsible for leading market access, reimbursement, HEOR and commercialization strategy consulting engagements to fully integrate traditional and non-traditional payer considerations into strategic plans and tactics.
She has been responsible for providing communication and pull-through strategies for payer and decision-maker engagement for numerous clients across a multitude of therapy areas. Susan has authored over 200 peer reviewed publications and presentations.
Susan received her BS in Pharmacy, University of North Carolina, Chapel Hill, NC and a Doctor of Pharmacy degree, University of Kentucky, Lexington, KY. Additionally, she completed a Residency and a Fellowship in Pediatric Pharmacotherapy and Pharmacokinetics, University of Tennessee, Memphis, TN. Susan also has completed an MPH in Health Policy and Administration, University of North Carolina, Chapel Hill, NC.
Key accomplishments
Adjunct Assistant Professor at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.
Key projects
- Earnshaw S, Mullins D, Brogan A, Hogue S. Building a budget impact model: budget impact analysis training. Presented at the ISPOR In-person Training Program; September 12-13, 2017. New Brunswick, NJ, USA and November 16-17, 2016 Durham, NC, USA
- While at GSK, worked extensively with the WHO and the Tobacco Free Initiative with respect to projecting the health and economic consequences of smoking and the benefits to cessation in 26 countries and delivering targeted health economics presentations aimed at regional MoH decision making.
Key publications
- Brogan AP, DeMuro C, Barrett AM, D’Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. J Manag Care Spec Pharm. 2017 Feb;23(2):124-34.
- White MV, Silvia S, Muniz R, Herrem C, Hogue SL. Prevalence and triggers of anaphylactic events in schools. Allergy Asthma Proc. 2017; 38:286 –293.
- Hogue SL, Goss D, Hollis K, Silvia S; White MV. Training and administration of epinephrine auto-injectors for anaphylaxis treatment in US schools: results from the EpiPen4Schools® pilot survey. J Asthma Allergy. 2016;9:109-15.
- Hogue S, Brogan AP, DeMuro C, D’Alessio D, Bal V. Patient reported outcomes (PRO) in postprogression oncology: implications in health technology assessments (HTA) & payer decision making. Poster presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; November 7-11, 2015. Milan Italy. [abstract] Value Health. 2015;18(7):A487-8.
- Hogue S, Brogan AP, Croft E. Orphan and ultra-orphan technologies: European and Australian payer perceptions. Poster presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; November 7-11, 2015. Milan Italy. [abstract] Value Health;18:A681.
- Mauskopf JA, Hogue SL, Brogan AP. Competitive bidding for therapeutically-equivalent branded pharmaceuticals: promise or threat? Presented at the International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting; May 20, 2015. Philadelphia, PA.
- Hogue S, Scott A, van Amerongen D, Hollis K, McLeod L, Brogan AP. Payer and decision maker use of observational studies for health care reimbursement decisions. Presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013. New Orleans, LA
Education
- MPH, Health Policy and Administration, University of North Carolina, Chapel Hill, NC
- Fellowship, Pediatric Pharmacotherapy and Pharmacokinetics, University of Tennessee, Memphis, TN
- Residency, Pediatric Pharmacotherapy, University of Tennessee, Memphis, TN
- PharmD, University of Kentucky, Lexington, KY
- BS, Pharmacy, University of North Carolina, Chapel Hill, NC
Media
My letter
As my career has become more focused on the end result—the leveraging and communication of value to payers and end users of health care economic information, omega is an appropriate symbol to represent me. Omega reminds me of our purpose at AESARA, providing our clients with impactful strategies, tactics and innovative digital solutions to ultimately support decision makers and helping the end users, the patients gain access to important healthcare technologies.
